Published in final edited form as:

Cell Biochem Biophys. 2014 January ; 68(1): 25–35. doi:10.1007/s12013-013-9679-4.

Differential expression of dicer, miRNAs and inflammatory markers in diabetic *Ins2*^{+/-} Akita hearts

Vishalakshi Chavali*, Suresh C. Tyagi, and Paras K. Mishra*

Department of Physiology & Biophysics, School of Medicine, University of Louisville,
Kentucky-40202, USA

Abstract

Diabetic cardiomyopathy is a leading cause of morbidity and mortality, and *Insulin2* mutant (*Ins2*^{+/-}) Akita is a genetic mice model of diabetes relevant to humans. Dicer, miRNAs and inflammatory cytokines are associated with heart failure. However, the differential expression of miRNAs, dicer and inflammatory molecules are not clear in diabetic cardiomyopathy of Akita. We measured the levels of miRNAs, dicer, pro-inflammatory tumor necrosis factor alpha (TNF α), and anti-inflammatory interleukin 10 (IL-10) in C57BL/6J (WT) and Akita hearts. The results revealed increased heart to body weight ratio and robust expression of brain natriuretic peptide (BNP: a hypertrophy marker) suggesting cardiac hypertrophy in Akita. The multiplex RT-PCR, qPCR and immunoblotting showed up regulation of dicer whereas miRNA array elicited spread down regulation of miRNAs in Akita including dramatic down regulation of let-7a, miR-130, miR-142-3p, miR-148, miR-338, miR-345-3p, miR-384-3p, miR-433, miR-450, miR-451, miR-455, miR-494, miR-499, miR-500, miR-542-3p, miR-744, and miR-872. Conversely, miR-295 is induced in Akita. Cardiac TNF α is up regulated at mRNA (RT-PCR and qPCR), protein (immunoblotting), and cellular (immunohistochemistry and confocal microscopy) levels, and is robust in hypertrophic cardiomyocytes suggesting direct association of TNF α with hypertrophy. Contrary to TNF α , cardiac IL-10 is down regulated in Akita. In conclusion, induction of dicer and TNF α , and attenuation of IL-10 and majority of miRNAs contributes to diabetic cardiomyopathy in Akita.

Keywords

BNP; diabetes; heart failure; hypertrophy; IL-10; TNF α

Introduction

Insulin2 mutant (*Ins2*^{+/-}) Akita mouse is an attractive animal model for diabetes because *Insulin2* gene of mouse is an ortholog of human *Insulin*, and mutation in *Insulin* gene causes human juvenile diabetes (1). Akita mice become diabetic spontaneously at the age of 3–4

*Address of correspondence, Paras Kumar Mishra, pkmish01@louisville.edu; parasbhu2005@gmail.com, Chavali Vishalakshi, v0chav01@louisville.edu, Department of Physiology & Biophysics, School of Medicine, University of Louisville, 500 South Preston Street, HSC-A, Room-1216, Louisville, KY 40202, USA, Phone: 502-852-3627, Fax: 502-852-6239.

Conflict of Interest

Authors confirm that there are no conflicts of interest.

weeks and show robust hyperglycemia by 12 weeks (2–7). Therefore, it is a better than the induced diabetes models such as NOD-autoimmune depletion of beta cells (8), OVE 26-the non-specific gene expression of beta cells (9), and Streptozotocin- or Alloxan-chemicals destruction of beta cells (10–12). These mice develop cardiac fibrosis, endothelium-myocyte uncoupling (5;13), impaired contractility of cardiomyocytes and cardiac dysfunction (4;14). However, the role of microRNA (miRNA), dicer and inflammation in diabetic cardiomyopathy in Akita is nebulous.

MiRNAs are newly discovered, 19–23 nucleotides long, non-coding regulatory RNAs that modulate gene expression either by mRNA degradation or translational repression (15;16). The differential expression of miRNAs is associated with heart failure (17–22) and diabetes (23–26). The distinct role of individual miRNA in cardiac dysfunction is corroborated by the fact that alteration in the levels of miR-133 causes cardiac hypertrophy (27;28), arrhythmia (29–31), fibrosis (32;33) and epigenetic modifications (34). Therefore, it is important to assess the differential expression of miRNAs in the heart of diabetic Akita. Dicer is an RNase III endonuclease essential for maturation of all pre-miRNAs (26;35–40). Dicer is indispensable for cardiac development because targeted deletion of dicer causes impaired development of ventricular myocardium and pericardial edema that lead to embryonic lethality at day 12.5 (41). The cardiac-specific knock out of dicer causes progressive dilated cardiomyopathy and ultimately heart failure (42). Even the conditional deletion of dicer in postnatal myocardium induces cardiomyocytes dysfunction and sudden cardiac arrest (43). Therefore, dicer plays crucial role in cardiac development and maintenance of cardiac functions. Ablation of dicer also inhibits global miRNA maturation that causes disarray in miRNA mediated regulatory networks. Interestingly, dicer is also regulated by miRNAs such as let-7 in human lung cancer (44) and miR-103/107 in breast cancer (45). MiRNAs also regulates inflammatory molecules including pro-inflammatory cytokine tumor necrosis factor alpha (TNF α) and anti-inflammatory cytokine interleukin-10 (IL-10) (46–49). There is a dynamic change in the levels of TNF α and IL-10 during pathological myocardial remodeling (50). TNF α is not only produced by immune cells rather synthesized by cardiomyocytes in response to injury or stress (51). The infusion of pathological dose of TNF α promotes left ventricular dysfunction and remodeling in rats (52). TNF α is also associated with diabetes (53) and contributes to heart failure (54;55). On the other hand, IL-10 inhibits TNF α and ameliorates pathological cardiac remodeling (56–58). Since, inflammation exacerbates heart failure (59), it is important to assess the levels of TNF α and IL-10 in Akita hearts. Therefore, we determined the levels of dicer, miRNAs, TNF α and IL-10 in Akita hearts.

Materials and Methods

Animal models

Twelve week old male C57BL/6J and Ins2+/- Akita mice were procured from Jackson Laboratory (Bar harbor, ME, USA). Akita mice have same genetic background as C57BL/6J mice. Therefore, we used C57BL/6J as wild type (WT) control for Akita. Mice were kept in the animal facility of University of Louisville with normal chaw diet and drinking water in *ad libitum*. They were sacrificed following the protocol approved by the Institutional Care

and Use Committee of University of Louisville. The standard protocol and guidelines of National Institute of health (NIH) and *Guide for the care and Use of Laboratory Animals* and the regulation of the Animal Welfare Act was followed.

Experimental Protocols

For measuring the blood glucose level, mice were kept on fasting (without food but with drinking water) for 8 hrs. To collect blood, tail vein was punctured and 1–2 drops of blood was transferred onto glucose strips of glucometer. The diabetics' mice have the blood glucose level 250 mg/dL and WT mice have 80mg/dL. Mice (both **diabetic and WT**) were anaesthetized with tribromoethanol (240mg/kg body weight, i. p.) and hearts were extracted under deep anesthesia. For RNA and protein extraction, hearts were snap frozen in liquid nitrogen and stored at -80°C . For histological sections, hearts were arrested in diastole by injecting 0.2ml/100g body weight of a 20% KCl (i. v.) and perfused with 0.9% saline (Teknova, CA, USA, Catalogue # S5815). They were fixed in 4% paraformaldehyde and embedded with tissue freezing medium for cryosectioning (5 μM). For all the experiments, sample size (n) was at least 5.

RNA extraction and quality assessment

The *miRVana* RNA isolation kit Ambion (Part Number #AM1560) was used for RNA isolation. The quality and quantity of RNA was analyzed by NanoDrop 1000, where the ratio of 260: 280 and 260: 230 with a value of ~ 2 was considered as good quality RNA. The detailed protocol is described elsewhere (60).

Semi-quantitative RT-PCR and quantitative qPCR

We used 1 μg RNA for reverse transcribed by two step protocol of Promega Kit (Promega, WI, USA, # A3800) as elaborated in our previous publication (60). The PCR program for amplification of dicer, TNF α , IL-10 and 18S was 95°C –7.00 min, (95°C –0.50min, 55°C –1.00 min, 72°C –1.00 min) $\times$ 34, 72°C –5.00 min and 4°C for infinity. As a loading control, 18S (Ambion # AM1716) was used. The primers used for dicer, TNF α , IL-10 and BNP are as follows: dicer-Forward: 5'atgcaaaaaggaccgtgttc3', Reverse: 5'caaggcgacatagcaagtca3'; TNF α -Forward: 5'gccgatttgctatctcatcac3', Reverse: 5'tgggtagagaatggatgaac3'; IL-10-Forward: 5'agaaatcaaggagcatttga3', Reverse: 5'acactcgctcagagacagat3'; and BNP-Forward: 5'ctgtcccatgatattctgtt3', Reverse: 5'taagatatgctgcccaat3'.

For gel electrophoresis of RT-PCR product, 1% agarose with 0.008 % ethidium bromide was used. The bands were observed under UV light and their intensity was analyzed by ChemiDoc device (BioRad, CA, USA).

For quantitative amplification (qPCR) of mRNA, Stratagene Mx3000P Real-time PCR device was employed. The Syber-green method was used with the PCR cycle of 95°C –10 min; (95°C –0.30 min, 55°C –1.00 min, 72°C –0.30 min) $\times$ 40; 95°C –1.00, and 55°C –0.30 min. The extended protocol is reported in our previous publication (60).

Multiplex-RT-PCR

To rule out the variation in RNA quantity and quality, and initial quantization errors during PCR, we used multiplex RT-PCR to amplify *dicer* in WT and Akita hearts. Multiplex RT-PCR amplifies two sets of primer in a single PCR, where one primer set acts as invariant endogenous control (18S), while the other amplifies the target gene (*dicer*, IL10 TNF α and BNP). Gel electrophoresis show two bands; one for endogenous control and other for the target gene.

MiRNA Assay

The miRNA array and individual assay was performed using Applied Biosystems kit and following their protocols. The Taqman microRNA reverse transcription kit (Part # 4366596), miR-223 (Part #007896) and sno234 (endogenous control) (Part # 1234) were used and the protocol is elaborated elsewhere (60).

Protein extraction and Western Blotting

Proteins were extracted from snap frozen hearts using Radio-Immuno-Precipitation Assay (RIPA, catalogue # BP-115D, Boston BioProducts, MA, USA) lyses buffer. The quantity of proteins was estimated by Bradford method using SoftMax Pro 4.6 program and Molecular Devices plate reader. The routine Western blotting was performed using SDS-PAGE gel electrophoresis. The primary antibodies of TNF α (LS Biosciences, WA, USA; # C18838), IL-10 (LS Biosciences, WA, USA; # B4913), *Dicer* (Santa Cruz; # sc-30226) and GAPDH (Millipore, CA, USA; # MAB 374) were diluted in the ratio of 1: 1000. The secondary antibodies, anti-mouse IgG-HRP (Santa Cruz Biotech; # sc-2005) and anti-rabbit IgG-HRP (Santa Cruz Biotech; #sc 2054) were diluted in the ratio of 1:3000. We also used secondary antibody for molecular size marker (BioRad Precision Protein Strep Tactin-HRP conjugate, (Bio-Rad; # 161-0381). The membranes were developed and band intensity was analyzed by ChemiDoc software (BioRad, CA, USA).

Multiplex-immunoblotting

To analyze the expression of target (TNF α) and control (GAPDH) proteins simultaneously, we incubated the nitrocellulose membranes with the primary antibodies of both TNF α and GAPDH. Similarly, the secondary antibodies corresponding to both TNF α and GAPDH were used. The membranes were developed as routine Western blotting and band intensity was analyzed for quantification.

Immunohistochemistry (IHC) and confocal microscopy

The IHC and confocal microscopy protocols were same as described earlier (13;61). In brief, histological sections of the heart from WT and Akita mice were washed with Phosphate Buffered Saline (PBS) (Invitrogen, GIBCO, #14190), permeabilized with 0.02% Triton X-100 (Fisher BioReagents, #BP-151) for 20 min, washed with PBS (three time for 5 min), blocked with 1% BSA in PBS, incubated with TNF α primary antibody (LS Biosciences, WA, USA; # C18838) diluted in the ratio of 1:100 for overnight at 4°C, washed with PBS, incubated with anti-rabbit Alexa-fluor 647 (Invitrogen; #A21245) diluted in the ratio of 1: 200 for 2 hr at room temperature, washed with PBS, incubated with DAPI (1: 1000 dilution)

for 30 min, mounted with FluoroGel (GTX; #28214) and observed under confocal microscope (Olympus). The intensity of red color was determined by Image-Pro software to compare the cellular expression of TNF α in WT and Akita hearts.

Statistical analyses

All the statistical values were presented as mean $\pm$ SE. Student t-test was performed to calculate the differences in mean between two groups. A p-value of <0.05 was considered as statistically significant difference.

Results

Cardiac hypertrophy in Akita

The geometrical shape of heart in WT is elongated (American football) but in Akita, it is changed to round shape (soccer ball) (Fig.1 A i), which is common in dilated cardiomyopathy (62). To determine cardiac hypertrophy, we measured the heart to body weight ratio (HW/BW) in WT and Akita hearts. The significant increase in HW/BW in Akita (Fig.1 A ii) suggests cardiac hypertrophy. To corroborate the finding at molecular level, we measured the levels of BNP (hypertrophy marker) by qPCR in the heart tissue of both WT and Akita. There is robust up regulation of BNP in Akita hearts (Fig. 1B) extending support to cardiac hypertrophy.

Dicer is induced in Akita hearts

Dicer level is low in end-stage heart failure but elevated in the hearts with left ventricle assist device (LVAD) (42). Therefore, we measured dicer at mRNA and protein levels in WT and Akita hearts. The multiplex-RT-PCR (Fig. 2A (i) and (ii)) and qPCR (Fig. 2B) show increased transcription of dicer in Akita, which is translated into protein (Fig 2 C i and ii). The increased level of dicer is similar to the condition of LVAD, where the heart is in recovery stage (42).

MiRNAs are attenuated in Akita hearts

Since differential expression of miRNAs contributes to pathological cardiac remodeling leading to heart failure (18;26), we measured the levels of miRNAs in WT and Akita hearts using miRNA array. The miRNA array analyses revealed that out of 242 miRNAs, 65 miRNAs are attenuated, where let-7a, miR-345-3p, miR-384-3p, miR-433 and miR-455 are ~ 80% down regulated in Akita (Fig. 3A and B). Conversely, miR-295 is induced (~3 fold up regulated) in Akita (Fig. 3B). We also confirmed the results by individual miRNA assay, which is in line with the miRNA array analyses (Fig. 3C and D). Since miR-223 is anti-inflammatory and cardio-protective (63;64), we also measured the levels of miR-223. The results show significant down regulation of miR-223 in Akita hearts (Fig. 3E).

TNF α is induced and associated with cardiac hypertrophy in Akita

Since TNF α is a pro-inflammatory cytokine that contributes to heart failure (54;55), we measure the levels of TNF α in WT and Akita hearts. The RT-PCR (Fig. 4A i and ii), and qPCR (Fig. 4B) results show significant up regulation of TNF α mRNA in Akita suggesting

its increased transcription. We used two endogenous controls (18s and GAPDH) to verify the induction of TNF α in Akita hearts (Fig. 4A and B). The multiplex –immunoblotting show that transcriptional message is translated at protein level in Akita hearts (Fig. 4C i and ii). We also determined the cellular levels of TNF α in WT and Akita hearts using IHC and confocal microscopy. There is increased expression of TNF α in Akita hearts (Fig. 4Di and ii). In the ventricular sections of Akita hearts, TNF α is mostly localized in the hypertrophic (comparatively bigger in size than the normal cardiomyocytes) cardiomyocytes (indicated by arrow), and almost absent in the normal size cardiomyocytes (indicated by star) (Fig. 4E). The localization of TNF α with hypertrophic cardiomyocytes suggests that TNF α is directly associated with cardiac hypertrophy in diabetic Akita.

IL-10 is attenuated in Akita hearts

The anti-inflammatory IL-10 is measured in WT and Akita hearts at both mRNA and protein levels. The RT-PCR (Fig. 5A i and ii) and qPCR (Fig. 5B) analyses show inhibition of transcription of IL-10 in Akita hearts. The immunoblotting results revealed that mRNA message is translated at protein levels in Akita (Fig. 5C). The mitigation of IL-10 suggests inhibition of anti-inflammatory cytokine in Akita hearts.

Discussion

Despite development in therapy regime, heart failure is a leading cause of morbidity and mortality in the world (65). The incidence of heart failure increases 2–4 folds with diabetes (66), which is rapidly increasing across the globe (67;68). However, the mechanism of heart failure in diabetes is still elusive. The newly discovered non-coding, tiny miRNAs are emerged as novel class of regulatory RNA that plays pivotal role in diabetes and heart failure (18;25;26;69–71). It is documented that differential expression of specific miRNA contributes to heart failure such as miR-1, -133, -150 in hypertrophy, miR-29, -133 in fibrosis, miR-1, -133 in arrhythmia, and miR-126 in angiogenesis (26;31). The miRNA maturation enzyme dicer is also reported to alter in the pathological and reverse cardiac remodeling (42). It is documented that miRNA regulates inflammation (48;64;72;73), which is induced in stress condition and contributes to heart failure (53;59;74;75). The pro-inflammatory TNF α plays key role in myocardial remodeling (54–56) and blocking of TNF α reverses the LV remodeling (55). On contrary, induction of anti-inflammatory IL-10 suppresses TNF α (56), and attenuates LV remodeling after myocardial infarction (MI) (57). The genetic deletion of IL-10 exacerbates but IL-10 treatment ameliorates pressure overload induced pathological cardiac remodeling (58) suggesting that IL-10 is a potent anti-inflammatory cytokine. Therefore, we investigated the cardiac levels of dicer, miRNAs, TNF α and IL-10 in diabetic Akita.

It is reported that the geometry of left ventricle (LV) alters to spherical dilatation in the apex in the failing heart (76). We found that shape of Akita heart has tendency to become spherical in the apical region of LV when compared to the WT heart (Fig 1A i). It extends support to cardiomyopathy of Akita hearts (14;77). The pathological condition of the heart is also evaluated by cardiac hypertrophy, where cardiomyocytes increase in size making the heart bigger than the normal size. The cardiac hypertrophy often is assessed by HW/BW

ratio and at molecular level by BNP expression. In Akita, increase in HW/BW (Fig 1A ii) and significant up regulation of BNP (Fig 1B) suggest cardiac hypertrophy. It supports pathological cardiac remodeling and dysfunction in diabetes (4;5;77). These changes are accompanied by induction of dicer both at mRNA and protein levels (Fig 2Ai–Cii). However, miRNAs are largely attenuated (Fig 3A–E) except miR-295 (Fig3 B). Since targeted deletion of dicer attenuates mature miRNAs (42), up regulation of dicer is anomalous to down regulation of miRNAs in Akita hearts. In the failing heart dicer is significantly down regulated but LVAD improves dicer to a moderate level (42). The induction of dicer in Akita can be explained by simulating the condition of the heart maneuvering to reverse the pathological remodeling as in case of LVAD. The spread down regulation of miRNAs in Akita hearts suggests inhibition of biogenesis of majority of miRNAs in diabetes. The miRNA profiling revealed several candidate miRNAs such as let-7a, miR-130a, -142-3p, -148, -338, -345-3p, -384-3p, -433, -450, -451, -455, -499, -500, -542-3p, -744, and -872, which are down regulated, and miR-295, which is up regulated in diabetic Akita (Fig 3 A–B). It is reported that miR-130a is involved in angiogenesis (78). In Akita, miR-130a is ~70% down regulated that may have implications on angiogenesis. Similarly, inhibition of miR-133a is associated with cardiac hypertrophy (27), fibrosis (33) and matrix remodeling (79). The cardiac hypertrophy (Fig 1Aii and B) and fibrosis (5) in Akita is in line with the above findings. The only miRNA we found up regulated in Akita is miR-295 (Fig 3A). It is documented that miR-295 is a mammalian –specific miRNA that express especially in early embryonic stage (80). In the failing heart, miRNAs undergo fetal reprogramming that is switching of expression profile from adult to embryonic condition (81). Fetal reprogramming is an adaptive mechanism to recover from adverse condition. The ~3 fold increase in the levels of miR-295 suggests pathological condition of Akita hearts. The miR-223 is an anti-inflammatory miRNA (82). The attenuation of miR-223 in Akita hearts suggest increased inflammation. Although inflammation can be cardioprotective in damaged myocardium if triggered ephemerally (83), chronic inflammation is detrimental (84). The robust up regulation of pro-inflammatory TNF α in Akita at mRNA (Fig 4Ai–B), protein (Fig 4Ci–ii) and cellular (Fig 4Di–ii) levels corroborates induction of inflammation in Akita hearts. Since TNF α causes LV remodeling (54;55), and beta-adrenergic receptor-mediated cardiac hypertrophy (85), we localized TNF α at cellular level both in normal and hypertrophic cardiomyocytes. The increased level of TNF α in the hypertrophic cardiomyocytes (shown by arrow head in Fig 4E), and decreased level of TNF α in normal cardiomyocytes (pointed with star in Fig 4E) suggests a direct association of TNF α with cardiac hypertrophy in Akita. The increased inflammation is also attributed to the inhibition of IL-10. It is documented that IL-10 suppresses TNF α induced cardiomyocytes apoptosis (56). Also, IL-10 inhibits inflammation and mitigates pathological LV remodeling (57). We found that IL-10 is down regulated in Akita both at mRNA (Fig 5Ai–B) and protein (Fig 5Ci–ii) levels indicating the inflammation mediated cardiac dysfunction in Akita.

Conclusion

Diabetic cardiomyopathy in Akita is associated with differential expression of dicer, miRNAs, TNF α and IL-10. The localization of TNF α in hypertrophic cardiomyocytes

points to role of TNF in cardiac hypertrophy. Our results revealed several novel putative candidate miRNAs involved in diabetic cardiomyopathy.

Acknowledgments

The financial supports from American Heart Association grant (11BGIA 7690055) and National Institute of Health (HL-113281) to P.K.M. and National Institute of Health (HL-108621 and HL-74185) to S.C.T. is gratefully acknowledged.

References

Reference List

- Garin I, Edghill EL, Akerman I, Rubio-Cabezas O, Rica I, Locke JM, et al. Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis. *Proc Natl Acad Sci U S A*. 2010 Feb 16; 107(7):3105–3110. [PubMed: 20133622]
- Barber AJ, Antonetti DA, Kern TS, Reiter CE, Soans RS, Krady JK, et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. *Invest Ophthalmol Vis Sci*. 2005 Jun; 46(6):2210–2218. [PubMed: 15914643]
- Chang JH, Paik SY, Mao L, Eisner W, Flannery PJ, Wang L, et al. Diabetic kidney disease in FVB/NJ Akita mice: temporal pattern of kidney injury and urinary nephrin excretion. *PLoS One*. 2012; 7(4):e33942. [PubMed: 22496773]
- Mishra PK, Givvimani S, Metreveli N, Tyagi SC. Attenuation of beta2-adrenergic receptors and homocysteine metabolic enzymes cause diabetic cardiomyopathy. *Biochem Biophys Res Commun*. 2010 Oct 15; 401(2):175–181. [PubMed: 20836991]
- Mishra PK, Tyagi N, Sen U, Joshua IG, Tyagi SC. Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol. *Cardiovasc Diabetol*. 2010; 9:49. [PubMed: 20828387]
- Izumi T, Yokota-Hashimoto H, Zhao S, Wang J, Halban PA, Takeuchi T. Dominant negative pathogenesis by mutant proinsulin in the Akita diabetic mouse. *Diabetes*. 2003 Feb; 52(2):409–416. [PubMed: 12540615]
- Wang J, Takeuchi T, Tanaka S, Kubo SK, Kayo T, Lu D, et al. A mutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse. *J Clin Invest*. 1999 Jan; 103(1):27–37. [PubMed: 9884331]
- Hartemann A, Bourron O. Interleukin-2 and type 1 diabetes: New therapeutic perspectives. *Diabetes Metab*. 2012 Jul 5.
- Epstein PN, Overbeek PA, Means AR. Calmodulin-induced early-onset diabetes in transgenic mice. *Cell*. 1989 Sep 22; 58(6):1067–1073. [PubMed: 2673540]
- Li Y, Hamasaki T, Teruya K, Nakamichi N, Gadek Z, Kashiwagi T, et al. Suppressive effects of natural reduced waters on alloxan-induced apoptosis and type 1 diabetes mellitus. *Cytotechnology*. 2012 May; 64(3):281–297. [PubMed: 22143345]
- Li YY, Liu HH, Chen HL, Li YP. Adipose-derived mesenchymal stem cells ameliorate STZ-induced pancreas damage in type 1 diabetes. *Biomed Mater Eng*. 2012 Jan 1; 22(1):97–103. [PubMed: 22766707]
- Yaghmaei P, Esfahani-Nejad H, Ahmadi R, Hayati-Roodbari N, Ebrahim-Habibi A. Maternal zinc intake of Wistar rats has a protective effect in the alloxan-induced diabetic offspring. *J Physiol Biochem*. 2012 Jun 23.
- Mishra PK, Chavali V, Metreveli N, Tyagi SC. Ablation of MMP9 induces survival and differentiation of cardiac stem cells into cardiomyocytes in the heart of diabetics: a role of extracellular matrix. *Can J Physiol Pharmacol*. 2012 Mar; 90(3):353–360. [PubMed: 22394373]
- Patel VB, Bodiga S, Basu R, Das SK, Wang W, Wang Z, et al. Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis. *Circ Res*. 2012 May 11; 110(10):1322–1335. [PubMed: 22474255]

15. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell*. 2004 Jan 23; 116(2):281–297. [PubMed: 14744438]
16. Bartel DP. MicroRNAs: target recognition and regulatory functions. *Cell*. 2009 Jan 23; 136(2): 215–233. [PubMed: 19167326]
17. Kawashima T, Shioi T. MicroRNA, emerging role as a biomarker of heart failure. *Circ J*. 2011; 75(2):268–269. [PubMed: 21206130]
18. Mishra PK, Tyagi N, Kumar M, Tyagi SC. MicroRNAs as a therapeutic target for cardiovascular diseases. *J Cell Mol Med*. 2009 Apr; 13(4):778–789. [PubMed: 19320780]
19. Ono K, Kuwabara Y, Han J. MicroRNAs and cardiovascular diseases. *FEBS J*. 2011 May; 278(10):1619–1633. [PubMed: 21395978]
20. Papageorgiou N, Tousoulis D, Androulakis E, Siasos G, Briasoulis A, Vogiatzi G, et al. The role of microRNAs in cardiovascular disease. *Curr Med Chem*. 2012; 19(16):2605–2610. [PubMed: 22489721]
21. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. *Circ Res*. 2007 Feb 16; 100(3):416–424. [PubMed: 17234972]
22. van RE, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. *Proc Natl Acad Sci U S A*. 2006 Nov 28; 103(48):18255–18260. [PubMed: 17108080]
23. Greco S, Fasanaro P, Castelvechio S, D'Alessandra Y, Arcelli D, Di DM, et al. MicroRNA dysregulation in diabetic ischemic heart failure patients. *Diabetes*. 2012 Jun; 61(6):1633–1641. [PubMed: 22427379]
24. Guay C, Roggli E, Nesca V, Jacovetti C, Regazzi R. Diabetes mellitus, a microRNA-related disease? *Transl Res*. 2011 Apr; 157(4):253–264. [PubMed: 21420036]
25. Kantharidis P, Wang B, Carew RM, Lan HY. Diabetes complications: the microRNA perspective. *Diabetes*. 2011 Jul; 60(7):1832–1837. [PubMed: 21709278]
26. Tyagi AC, Sen U, Mishra PK. Synergy of microRNA and stem cell: a novel therapeutic approach for diabetes mellitus and cardiovascular diseases. *Curr Diabetes Rev*. 2011 Nov; 7(6):367–376. [PubMed: 21864292]
27. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, et al. MicroRNA-133 controls cardiac hypertrophy. *Nat Med*. 2007 May; 13(5):613–618. [PubMed: 17468766]
28. Feng B, Chen S, George B, Feng Q, Chakrabarti S. miR133a regulates cardiomyocyte hypertrophy in diabetes. *Diabetes Metab Res Rev*. 2010 Jan; 26(1):40–49. [PubMed: 20013939]
29. Belevych AE, Sansom SE, Terentyeva R, Ho HT, Nishijima Y, Martin MM, et al. MicroRNA-1 and -133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. *PLoS One*. 2011; 6(12):e28324. [PubMed: 22163007]
30. Luo X, Lin H, Pan Z, Xiao J, Zhang Y, Lu Y, et al. Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. *J Biol Chem*. 2008 Jul 18; 283(29):20045–20052. [PubMed: 18458081]
31. Xiao J, Luo X, Lin H, Zhang Y, Lu Y, Wang N, et al. MicroRNA miR-133 represses HERG K⁺ channel expression contributing to QT prolongation in diabetic hearts. *J Biol Chem*. 2007 Apr 27; 282(17):12363–12367. [PubMed: 17344217]
32. Castoldi G, Di Gioia CR, Bombardi C, Catalucci D, Corradi B, Gualazzi MG, et al. MiR-133a regulates collagen 1A1: potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension. *J Cell Physiol*. 2012 Feb; 227(2):850–856. [PubMed: 21769867]
33. Matkovich SJ, Wang W, Tu Y, Eschenbacher WH, Dorn LE, Condorelli G, et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. *Circ Res*. 2010 Jan 8; 106(1):166–175. [PubMed: 19893015]
34. Chavali V, Tyagi SC, Mishra PK. MicroRNA-133a regulates DNA methylation in diabetic cardiomyocytes. *Biochem Biophys Res Commun*. 2012 Jul 27.
35. Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ, et al. Dicer is essential for mouse development. *Nat Genet*. 2003 Nov; 35(3):215–217. [PubMed: 14528307]

36. Davis TH, Cuellar TL, Koch SM, Barker AJ, Harfe BD, McManus MT, et al. Conditional loss of Dicer disrupts cellular and tissue morphogenesis in the cortex and hippocampus. *J Neurosci*. 2008 Apr 23; 28(17):4322–4330. [PubMed: 18434510]
37. Koralov SB, Muljo SA, Galler GR, Krek A, Chakraborty T, Kanellopoulou C, et al. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. *Cell*. 2008 Mar 7; 132(5): 860–874. [PubMed: 18329371]
38. Kuehnbacher A, Urbich C, Zeiher AM, Dimmeler S. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. *Circ Res*. 2007 Jul 6; 101(1):59–68. [PubMed: 17540974]
39. Lynn FC, Skewes-Cox P, Kosaka Y, McManus MT, Harfe BD, German MS. MicroRNA expression is required for pancreatic islet cell genesis in the mouse. *Diabetes*. 2007 Dec; 56(12): 2938–2945. [PubMed: 17804764]
40. Murchison EP, Stein P, Xuan Z, Pan H, Zhang MQ, Schultz RM, et al. Critical roles for Dicer in the female germline. *Genes Dev*. 2007 Mar 15; 21(6):682–693. [PubMed: 17369401]
41. Zhao Y, Ransom JF, Li A, Vedantham V, von DM, Muth AN, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1–2. *Cell*. 2007 Apr 20; 129(2):303–317. [PubMed: 17397913]
42. Chen JF, Murchison EP, Tang R, Callis TE, Tatsuguchi M, Deng Z, et al. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. *Proc Natl Acad Sci U S A*. 2008 Feb 12; 105(6):2111–2116. [PubMed: 18256189]
43. da Costa Martins PA, Bourajjaj M, Gladka M, Kortland M, van Oort RJ, Pinto YM, et al. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. *Circulation*. 2008 Oct 7; 118(15):1567–1576. [PubMed: 18809798]
44. Tokumaru S, Suzuki M, Yamada H, Nagino M, Takahashi T. let-7 regulates Dicer expression and constitutes a negative feedback loop. *Carcinogenesis*. 2008 Nov; 29(11):2073–2077. [PubMed: 18700235]
45. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, et al. A MicroRNA targeting dicer for metastasis control. *Cell*. 2010 Jun 25; 141(7):1195–1207. [PubMed: 20603000]
46. Moschos SA, Williams AE, Perry MM, Birrell MA, Belvisi MG, Lindsay MA. Expression profiling in vivo demonstrates rapid changes in lung microRNA levels following lipopolysaccharide-induced inflammation but not in the anti-inflammatory action of glucocorticoids. *BMC Genomics*. 2007; 8:240. [PubMed: 17640343]
47. Perry MM, Moschos SA, Williams AE, Shepherd NJ, Larner-Svensson HM, Lindsay MA. Rapid changes in microRNA-146a expression negatively regulate the IL-1beta-induced inflammatory response in human lung alveolar epithelial cells. *J Immunol*. 2008 Apr 15; 180(8):5689–5698. [PubMed: 18390754]
48. Roy S, Sen CK. MiRNA in innate immune responses: novel players in wound inflammation. *Physiol Genomics*. 2011 May 1; 43(10):557–565. [PubMed: 21139022]
49. Wang JF, Yu ML, Yu G, Bian JJ, Deng XM, Wan XJ, et al. Serum miR-146a and miR-223 as potential new biomarkers for sepsis. *Biochem Biophys Res Commun*. 2010 Mar 26; 394(1):184–188. [PubMed: 20188071]
50. Zeng JR, Xu XL, Yu XJ, Hou J, Xu TJ, Mi M, et al. [Dynamic correlation of TNF-alpha and IL-10 with myocardial remodeling induced by pressure overload in rats]. *Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi*. 2012 Jul; 28(7):699–701. [PubMed: 22768858]
51. Cain BS, Meldrum DR, Dinarello CA, Meng X, Joo KS, Banerjee A, et al. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. *Crit Care Med*. 1999 Jul; 27(7):1309–1318. [PubMed: 10446825]
52. Bozkurt B, Kribbs SB, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. *Circulation*. 1998 Apr 14; 97(14):1382–1391. [PubMed: 9577950]
53. Calle MC, Fernandez ML. Inflammation and type 2 diabetes. *Diabetes Metab*. 2012 Jun; 38(3): 183–191. [PubMed: 22252015]

54. Bradham WS, Bozkurt B, Gunasinghe H, Mann D, Spinale FG. Tumor necrosis factor- α and myocardial remodeling in progression of heart failure: a current perspective. *Cardiovasc Res*. 2002 Mar; 53(4):822–830. [PubMed: 11922892]
55. Bradham WS, Moe G, Wendt KA, Scott AA, Konig A, Romanova M, et al. TNF- α and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. *Am J Physiol Heart Circ Physiol*. 2002 Apr; 282(4):H1288–H1295. [PubMed: 11893563]
56. Dhingra S, Bagchi AK, Ludke AL, Sharma AK, Singal PK. Akt regulates IL-10 mediated suppression of TNF α -induced cardiomyocyte apoptosis by upregulating Stat3 phosphorylation. *PLoS One*. 2011; 6(9):e25009. [PubMed: 21949832]
57. Krishnamurthy P, Rajasingh J, Lambers E, Qin G, Losordo DW, Kishore R. IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR. *Circ Res*. 2009 Jan 30; 104(2):e9–e18. [PubMed: 19096025]
58. Verma SK, Krishnamurthy P, Barefield D, Singh N, Gupta R, Lambers E, et al. Interleukin-10 Treatment Attenuates Pressure Overload-Induced Hypertrophic Remodeling and Improves Heart Function via Signal Transducers and Activators of Transcription 3-Dependent Inhibition of Nuclear Factor- κ B. *Circulation*. 2012 Jul 24; 126(4):418–429. [PubMed: 22705886]
59. Barac A, Wang H, Shara NM, de SG, Carter EA, Umans JG, et al. Markers of inflammation, metabolic risk factors, and incident heart failure in American Indians: the Strong Heart Study. *J Clin Hypertens (Greenwich)*. 2012 Jan; 14(1):13–19. [PubMed: 22235819]
60. Mishra PK, Tyagi N, Kundu S, Tyagi SC. MicroRNAs are involved in homocysteine-induced cardiac remodeling. *Cell Biochem Biophys*. 2009; 55(3):153–162. [PubMed: 19669742]
61. Mishra PK, Awe O, Metreveli N, Qipshidze N, Joshua IG, Tyagi SC. Exercise mitigates homocysteine - beta2-adrenergic receptor interactions to ameliorate contractile dysfunction in diabetes. *Int J Physiol Pathophysiol Pharmacol*. 2011; 3(2):97–106. [PubMed: 21760968]
62. Salgo IS, Tsang W, Ackerman W, Ahmad H, Chandra S, Cardinale M, et al. Geometric assessment of regional left ventricular remodeling by three-dimensional echocardiographic shape analysis correlates with left ventricular function. *J Am Soc Echocardiogr*. 2012 Jan; 25(1):80–88. [PubMed: 22000777]
63. Schaefer JS, Montufar-Solis D, Vigneswaran N, Klein JR. Selective upregulation of microRNA expression in peripheral blood leukocytes in IL-10 $^{-/-}$ mice precedes expression in the colon. *J Immunol*. 2011 Dec 1; 187(11):5834–5841. [PubMed: 22043014]
64. van, dV; Heymans, S.; Schroen, B. MicroRNA involvement in immune activation during heart failure. *Cardiovasc Drugs Ther*. 2011 Apr; 25(2):161–170. [PubMed: 21503626]
65. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. *Circulation*. 2012 Jan 3. 125(1):e2–e220. [PubMed: 22179539]
66. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. *Diabetes Care*. 2010 Jun; 33(6):1395–1402. [PubMed: 20508233]
67. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. *Diabetes Care*. 1998 Sep; 21(9):1414–1431. [PubMed: 9727886]
68. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care*. 2004 May; 27(5):1047–1053. [PubMed: 15111519]
69. Kawashima T, Shioi T. MicroRNA, emerging role as a biomarker of heart failure. *Circ J*. 2011; 75(2):268–269. [PubMed: 21206130]
70. Papageorgiou N, Tousoulis D, Androulakis E, Siasos G, Briasoulis A, Vogiati G, et al. The role of microRNAs in cardiovascular disease. *Curr Med Chem*. 2012; 19(16):2605–2610. [PubMed: 22489721]
71. Shantikumar S, Caporali A, Emanuelli C. Role of microRNAs in diabetes and its cardiovascular complications. *Cardiovasc Res*. 2012 Mar 15; 93(4):583–593. [PubMed: 22065734]

72. Huang Y, Crawford M, Higuera-Castro N, Nana-Sinkam P, Ghadiali SN. miR-46a regulates mechanotransduction and pressure-induced inflammation in small airway epithelium. *FASEB J*. 2012 Aug; 26(8):3351–3364. [PubMed: 22593544]
73. Zidar N, Bostjancic E, Glavac D, Stajer D. MicroRNAs, innate immunity and ventricular rupture in human myocardial infarction. *Dis Markers*. 2011; 31(5):259–265. [PubMed: 22048267]
74. Manabe I. Chronic inflammation links cardiovascular, metabolic and renal diseases. *Circ J*. 2011; 75(12):2739–2748. [PubMed: 22067929]
75. Rosner MH, Ronco C, Okusa MD. The role of inflammation in the cardio-renal syndrome: a focus on cytokines and inflammatory mediators. *Semin Nephrol*. 2012 Jan; 32(1):70–78. [PubMed: 22365165]
76. Monsefi N, Zierer A, Bakhtiary F, Vogl T, Ackermann H, Kleine P, et al. Spherical dilatation of the apex in failing left ventricles: a target for surgical remodelling techniques. *J Cardiovasc Surg (Torino)*. 2012 Aug; 53(4):545–552.
77. Basu R, Oudit GY, Wang X, Zhang L, Ussher JR, Lopaschuk GD, et al. Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. *Am J Physiol Heart Circ Physiol*. 2009 Dec; 297(6):H2096–H2108. [PubMed: 19801494]
78. Staszal T, Zapala B, Polus A, Sadakierska-Chudy A, Kiec-Wilk B, Stepień E, et al. Role of microRNAs in endothelial cell pathophysiology. *Pol Arch Med Wewn*. 2011 Oct; 121(10):361–366. [PubMed: 21946298]
79. Duisters RF, Tijssen AJ, Schroen B, Leenders JJ, Lentink V, van der M I, et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. *Circ Res*. 2009 Jan 30; 104(2):170–178. 6p. [PubMed: 19096030]
80. Medeiros LA, Dennis LM, Gill ME, Houbaviy H, Markoulaki S, Fu D, et al. Mir-290–295 deficiency in mice results in partially penetrant embryonic lethality and germ cell defects. *Proc Natl Acad Sci U S A*. 2011 Aug 23; 108(34):14163–14168. [PubMed: 21844366]
81. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. *Circulation*. 2007 Jul 17; 116(3):258–267. [PubMed: 17606841]
82. Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O, et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. *Nature*. 2008 Feb 28; 451(7182):1125–1129. [PubMed: 18278031]
83. Chao W. Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. *Am J Physiol Heart Circ Physiol*. 2009 Jan; 296(1):H1–H12. [PubMed: 19011041]
84. Mann DL, Topkara VK, Evans S, Barger PM. Innate immunity in the adult mammalian heart: for whom the cell tolls. *Trans Am Clin Climatol Assoc*. 2010; 121:34–50. [PubMed: 20697548]
85. Garlie JB, Hamid T, Gu Y, Ismahil MA, Chandrasekar B, Prabhu SD. Tumor necrosis factor receptor 2 signaling limits beta-adrenergic receptor-mediated cardiac hypertrophy in vivo. *Basic Res Cardiol*. 2011 Nov; 106(6):1193–1205. [PubMed: 21691899]

Figure 1. Comparative analysis of cardiac hypertrophy in WT and *Ins2*^{+/-} Akita mice

A (i). Representative heart morphology of WT and Akita with bar graph showing ratio of heart to body weight (HW/BW). **A (ii).** Representative longitudinal section of the heart from WT and Akita mice. **B (i).** The qPCR analysis of brain natriuretic peptide (BNP) in WT and Akita hearts. GAPDH is a loading control. Data are represented as mean $\pm$ SE. *, $p < 0.05$; $n = 4$.

B (ii) a. Representative immunohistochemistry figure of BNP (red color) in the WT and Akita hearts. Dapi (blue) color stains nuclei. **B (ii) b.** Bar graph showing the intensity of red color in the heart. *, $p < 0.05$; $n = 3$.

Figure 2. Differential expression of dicer in WT and *Ins2*^{+/-} Akita hearts

A. (i). Representative multiplex-RT-PCR of dicer and 18S in WT and Akita. The 18S RNA is a loading control. **(ii).** The bar graph show densitometry analyses of intensity of bands normalized with 18S. The values are mean $\pm$ SE. *, $p < 0.05$; $n = 4$. **B.** The qPCR analyses of dicer normalized with GAPDH in WT and Akita. **C. (i).** Representative band of immunoblotting of dicer in WT and Akita hearts. GAPDH is a loading control. **(ii).** The bar graph represents densitometry analyses of intensity of bands normalized with GAPDH. The values are mean $\pm$ SE. *, $p < 0.05$; $n = 4$.

A **B**

Figure 3. The miRNA profiling of WT and Akita hearts

A–B. The miRNA array shows attenuation of majority of miRNAs but induction of miR-295 in *Ins2*^{+/-} Akita. The sno234 is used as an endogenous control. **C–E.** Individual miRNA assay shows inhibition of miR-1 (C), miR-133 (D) and miR-223 (E) in *Ins2*^{+/-} Akita. The values are represented in fold change with standard error. *, $p < 0.05$. $n = 2$ (for array) and 4 for (individual assay).

Figure 4. Differential expression of TNFα in *Ins2*^{+/-} Akita hearts

A. (i). Representative RT-PCR of TNFα in WT and Akita hearts. The 18S RNA is a loading control. **(ii).** The bar graph represents densitometry analyses of band intensity (mean ± SE) normalized with 18S. *, $p < 0.05$, $n = 4$. **B.** The qPCR analyses of TNFα in WT and Akita hearts. GAPDH is an endogenous control. *, $p < 0.05$; $n = 4$. **C. (i).** Representative multiplex-immunoblotting of TNFα in WT and Akita hearts. GAPDH is a loading control. **(ii):** The densitometry analyses of band intensity (mean ± SE) normalized with GAPDH. *, $p < 0.05$, $n = 4$. **D. (i).** Representative immunohistochemistry of TNFα (red color). The 5μM cryosections of the heart are stained with TNFα primary and Texas Red secondary antibodies and observed under confocal microscope. The blue color (Dapi staining) is showing nucleus. **(ii).** The bar graph represents intensity of red color in WT and Akita. The values are presented as mean ± SE. *, $p < 0.05$; $n = 3$. **E.** The cellular localization of TNFα (red color) in hypertrophic (arrow head) and normal (star) cardiomyocytes of Akita. The blue color (Dapi staining) is showing nucleus.

Figure 5. Differential expression of IL-10 in *Ins2*^{+/-} Akita hearts

A. (i). Representative RT-PCR of IL-10 in WT and Akita. The 18S RNA is a loading control. **(ii).** The densitometry analyses of band intensity normalized with 18S in WT and Akita. The bar graph represents mean $\pm$ SE of band intensity determined by arbitrary scan unit. *, $p < 0.05$; $n = 4$. **B.** The qPCR analyses of IL-10 normalized with GAPDH in WT and Akita. **C. (i).** Representative immunoblots for IL-10 in WT and Akita. GAPDH is a loading control. **(ii):** The bar graph represents densitometry analyses of band intensity in scan arbitrary unit normalized with GAPDH in WT and Akita. The values are presented as mean $\pm$ SE. *, $p < 0.05$, $n = 4$.